Although PMX-DHP therapy previously demonstrated efficacy for the treatment of acute exacerbations of IPF [12, 15, 16], the mortality rate of anti-MDA-5 antibody positive patients with CADM-associated RPIPs remained poor despite additional PMX-DHP therapy. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.